The liver cancer drug Nexavar (sorafenib) has been rejected for the second time by NICE
After the drug was turned down by for NHS use in May, Bayer then proposed a patient-access scheme that would have reduced its cost to the health service.
This has now been rejected by NICE, which had earlier refused it for use on the NHS for the treatment of kidney cancer.
The latest setback for Bayer and partner Onyx Pharmaceuticals has been described by the company as a “blow for patients” suffering from hepatocellular carcinoma, which accounts for 80% of all primary liver tumours.
Nexavar has proved successful against liver and kidney cancers and has been trialled for use against lung and breast tumours.